Novo Nordisk sued over weight-loss drug spin. Now it’s doing the exact same thing

Novo Nordisk and Eli Lilly are battling for dominance in one of medicine’s largest and fastest-growing markets: drugs for obesity and weight loss. On Monday, Novo announced encouraging results for its experimental drug CagriSema. In a Phase 3 study of patients with type 2 diabetes, CagriSema produced 12.4% average weight loss after 60 weeks, compared […]

Read it at Washington Examiner ↗

← Front page